Minims Tetracainehydrochloride (Tetracaine Hydrochloride)

Tetracaine hydrochloride works by reversibly blocking voltage‑gated sodium channels on peripheral nerve membranes of the ocular surface. This blockade stops the initiation and propagation of nerve impulses, resulting in a localized loss of sensation that provides effective anesthesia of the cornea and surrounding tissues.

The appropriate dose of Minims Tetracainehydrochloride is determined by the prescribing clinician based on the specific procedure, patient age, and ocular condition. The product is applied as a few drops to the affected eye, and the exact volume and frequency are set by the healthcare professional.

Safety data for tetracaine hydrochloride in pregnancy and lactation are limited. The drug should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians should assess each case individually and discuss possible risks with the patient.

To order Minims Tetracainehydrochloride, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with other ophthalmic anesthetics such as proparacaine or lidocaine, tetracaine provides a slightly longer duration of corneal anesthesia and a rapid onset of action. Its ester‑type structure allows quick penetration of the corneal epithelium, making it suitable for brief procedures, while the safety profile is similar when used as directed.

Store Minims Tetracainehydrochloride at room temperature below 25 °C in its original container. Protect the solution from direct light, moisture and extreme temperatures. Keep the vial tightly sealed when not in use and discard any product that appears discolored or contaminated.

The product is administered as an ophthalmic drop. The prescriber directs the number of drops to place on the conjunctival sac of the target eye, typically just before the diagnostic or surgical procedure. The eye should be gently closed for a few seconds to allow even distribution of the anesthetic.

Serious risks, although rare, include corneal epithelial toxicity or ulceration, allergic contact keratitis, and severe ocular inflammation such as uveitis. These events require immediate ophthalmologic evaluation and discontinuation of the drug. Prompt reporting of any unexpected visual changes or severe discomfort is essential.

Patients with a known hypersensitivity to tetracaine, other ester‑type local anesthetics, or any component of the formulation should avoid using the product. It is also contraindicated in eyes with active severe infection, extensive corneal epithelial defects, or when the prescriber determines that alternative anesthesia methods are more appropriate.